Ex-Dividend Reminder: Amgen, U.S. Physical Therapy and Dynex Capital

Amgen (AMGN), U.S. Physical Therapy (USPH), and Dynex Capital (DX) are scheduled to trade ex-dividend on August 22, 2025. AMGN's $2.38 quarterly dividend is expected to reduce its share price by approximately 0.81%, USPH's $0.45 quarterly dividend by 0.53%, and DX's $0.17 monthly dividend by 1.36%, all else being equal. Amgen is also highlighted as a "future dividend aristocrats contender" with over 14 years of dividend growth, offering an annualized yield of 3.22%. Despite the impending ex-dividend adjustments, all three stocks were trading positively on the day.

Analysis

On August 22, 2025, Amgen (AMGN), U.S. Physical Therapy (USPH), and Dynex Capital (DX) will trade ex-dividend, triggering a technical price adjustment in their shares. Amgen, with a recent price of $295.55, will pay a $2.38 quarterly dividend, equating to an expected 0.81% price decrease and an annualized yield of 3.22%. Notably, Amgen is positioned as a "future dividend aristocrats contender," having a strong track record of over 14 consecutive years of dividend increases, which signals a robust capital return policy. In contrast, Dynex Capital offers a significantly higher annualized yield of 16.33% from its $0.17 monthly dividend, which corresponds to a larger expected price drop of 1.36%. U.S. Physical Therapy presents a more modest 2.12% annualized yield from its $0.45 quarterly dividend. Despite the impending ex-dividend price adjustments, all three stocks posted gains in Wednesday's trading session, with Amgen up approximately 1%, indicating positive underlying market sentiment that temporarily outweighed the technical dividend event.

Key Decisions for Investors

• Investors seeking dividend growth and reliability should consider Amgen's profile as a 'future dividend aristocrat' with over 14 years of increases and a solid 3.22% annualized yield, suggesting a stable component for a long-term income portfolio.
• The significantly higher 16.33% annualized yield from Dynex Capital warrants careful due diligence regarding its sustainability, as such returns often correlate with greater underlying risk compared to the more moderate yields of Amgen and U.S. Physical Therapy.
• Portfolio managers should account for the technical price drop on the August 22, 2025 ex-dividend date, as shares are expected to open lower in line with their respective dividend payouts, presenting a predictable factor for position timing and valuation.